At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 448 enrolled
Drug / intervention
Avacincaptad Pegol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
In Brief
A Phase 3 clinical trial evaluating Avacincaptad Pegol and Sham for Geographic Atrophy and Macular Degeneration. Completed, enrolled 448 participants across 205 sites in 20 countries.
Detailed Summary
The objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeographic Atrophy, Macular Degeneration
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czechia, Estonia, France, Germany, Hungary, Israel, Italy, Latvia, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJun 2020
Primary CompletionJul 2022
Study CompletionAug 2023
TodayJul 2026
First PostedJun 17, 2020
Enrollment StartJun 22, 2020
Primary CompletionJul 25, 2022
Study CompletionAug 22, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.0 years ago
Interventions
Avacincaptad Pegoldrug
Avacincaptad Pegol Intravitreal Injection
Shamdrug
Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)